If cardiovascular outcomes of tirzepatide are similar to GLP-1 RAs, the medication may be used by practitioners preferentially prior to using GLP-1 RAs in patients with or without diabetes who desire weight-loss
The risk-benefit, if you have obesity, is way in favor of using them, but its not a supplement where I would say, Go ahead, try it and see if it does something to you, says Dan Azagury, MD, medical director for the Stanford Lifestyle and Weight Management Center
Once a product leaves our facility, we can no longer verify its environmental exposure or structural integrity
The most common retatrutide side effects are nausea (28%), diarrhea (24%), constipation (21%), and vomiting (17%), with symptoms peaking around weeks 6-8 before substantially improving by week 12
There's no evidence saying these drugs cause C cell hyperplasia in humans, so the FDA gave it a black box warning until we know more
It is FDA-approved for weight loss and long-term weight management in adults and adolescents 12 years and older with obesity, as well as adults with overweight who have at least one weight-related health condition
